Rtz LH, Sargent D, et al. New response evaluation criteria in

Rtz LH, Sargent D, et al. New response evaluation criteria in strong tumours: 15857111 revised RECIST guideline. European journal of cancer 45: 228247. 33. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med four: 844847. 34. Engelsen IB, Epigenetics Stefansson IM, Akslen LA, Salvesen HB GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with higher proliferation and poor patient survival. Am J Obstet Gynecol 199: 543 e541547. 35. Salvesen HB, Das S, Akslen LA Loss of nuclear p16 protein expression is not linked with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res six: 153159. 36. Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, et al. Larger sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with higher versus low HER-2/neu expression in vitro. Gynecol Oncol 119: 140145. 37. Hiramatsu HP, Kikuchi Y, Seto H, Nagata I In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan in mixture with other aniticancer drugs. Anticancer Drugs 11: 573578. 38. Vandenput I, Trovik J, Leunen K, Wik E, Stefansson I, et al. Evolution in endometrial cancer: proof from an immunohistochemical study. Int J Gynecol Cancer 21: 316322. 39. Amant F, Mirza MR, Creutzberg CL Cancer from the corpus uteri. Int J Gynaecol Obstet 119 Suppl two: S110117. 40. Halle MK, Werner HM, Krakstad C, Birkeland E, Wik E, et al. Stratification based on high tumour cell content material in fresh frozen tissue promotes choice of aggressive endometrial carcinomas. Histopathology 60: 516519. 41. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, et al. Cell death modalities: classification and pathophysiological implications. Cell death and differentiation 14: 12371243. eight Stathmin Predicts Response in Endometrial Cancer 42. Taatjes DJ, Sobel BE, Budd RC Morphological and cytochemical determination of cell death by apoptosis. Histochemistry and cell biology 129: 3343. 43. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. Reporting recommendations for tumor marker prognostic research. Journal of the National Cancer Institute 97: 11801184. 44. Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, Burd B, Angeletti R, et al. Insights in to the mechanism of microtubule stabilization by Taxol. Proceedings with the National Academy of Sciences on the Usa of America 103: 1016610173. 45. Arslan C, Sari E, Aksoy S, Altundag K Variation in hormone receptor and HER-2 status involving main and metastatic breast cancer: overview from the literature. Professional opinion on therapeutic targets 15: 2130. 46. Khasraw M, Brogi E, Seidman AD The have to examine metastatic tissue in the time of progression of breast cancer: is re-biopsy a necessity or even a luxury Existing oncology Autophagy reports 13: 1725. 47. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with 48. 49. 50. 51. 52. distant metastases Annals of oncology: official journal from the European Society for Healthcare Oncology/ESMO 20: 14991504. Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, et al. Loss of GPER identifies new targets for therapy amongst a subgroup of ERalpha-positive endometrial cancer individuals with poor outcome. British journal of cancer 106: 16821688. Bi.Rtz LH, Sargent D, et al. New response evaluation criteria in solid tumours: 15857111 revised RECIST guideline. European journal of cancer 45: 228247. 33. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844847. 34. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 199: 543 e541547. 35. Salvesen HB, Das S, Akslen LA Loss of nuclear p16 protein expression will not be connected with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res six: 153159. 36. Paik D, Cocco E, Bellone S, Casagrande F, Bellone M, et al. Greater sensitivity to patupilone versus paclitaxel chemotherapy in principal uterine serous papillary carcinoma cell lines with higher versus low HER-2/neu expression in vitro. Gynecol Oncol 119: 140145. 37. Hiramatsu HP, Kikuchi Y, Seto H, Nagata I In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan in mixture with other aniticancer drugs. Anticancer Drugs 11: 573578. 38. Vandenput I, Trovik J, Leunen K, Wik E, Stefansson I, et al. Evolution in endometrial cancer: evidence from an immunohistochemical study. Int J Gynecol Cancer 21: 316322. 39. Amant F, Mirza MR, Creutzberg CL Cancer of the corpus uteri. Int J Gynaecol Obstet 119 Suppl two: S110117. 40. Halle MK, Werner HM, Krakstad C, Birkeland E, Wik E, et al. Stratification according to higher tumour cell content material in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology 60: 516519. 41. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, et al. Cell death modalities: classification and pathophysiological implications. Cell death and differentiation 14: 12371243. eight Stathmin Predicts Response in Endometrial Cancer 42. Taatjes DJ, Sobel BE, Budd RC Morphological and cytochemical determination of cell death by apoptosis. Histochemistry and cell biology 129: 3343. 43. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. Reporting suggestions for tumor marker prognostic studies. Journal of your National Cancer Institute 97: 11801184. 44. Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, Burd B, Angeletti R, et al. Insights in to the mechanism of microtubule stabilization by Taxol. Proceedings from the National Academy of Sciences in the Usa of America 103: 1016610173. 45. Arslan C, Sari E, Aksoy S, Altundag K Variation in hormone receptor and HER-2 status between key and metastatic breast cancer: assessment of the literature. Professional opinion on therapeutic targets 15: 2130. 46. Khasraw M, Brogi E, Seidman AD The ought to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or possibly a luxury Current oncology reports 13: 1725. 47. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, et al. Does confirmatory tumor biopsy alter the management of breast cancer sufferers with 48. 49. 50. 51. 52. distant metastases Annals of oncology: official journal of your European Society for Healthcare Oncology/ESMO 20: 14991504. Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, et al. Loss of GPER identifies new targets for therapy amongst a subgroup of ERalpha-positive endometrial cancer patients with poor outcome. British journal of cancer 106: 16821688. Bi.